Sensei Biotherapeutics (NASDAQ:FTH) Shares Gap Down – Here’s What Happened

Sensei Biotherapeutics, Inc. (NASDAQ:FTH) shares gapped down before the market opened on Thursday. The stock had previously closed at $21.51, but opened at $19.90. Sensei Biotherapeutics shares last traded at $21.0450, with a volume of 6,898 shares traded.

Analyst Ratings Changes

A number of analysts recently issued reports on the stock. TD Cowen assumed coverage on shares of Sensei Biotherapeutics in a report on Wednesday, September 9th. They set a “buy” rating on the stock. Needham & Company LLC assumed coverage on shares of Sensei Biotherapeutics in a report on Friday, August 21st. They issued a “buy” rating and a $56.00 price objective on the stock. JonesTrading assumed coverage on Sensei Biotherapeutics in a research note on Tuesday, August 4th. They issued a “buy” rating and a $55.00 price objective for the company. Oppenheimer initiated coverage on Sensei Biotherapeutics in a report on Tuesday, July 28th. They set an “outperform” rating and a $60.00 price objective on the stock. Finally, Citizens Jmp started coverage on Sensei Biotherapeutics in a report on Monday, July 20th. They set an “outperform” rating and a $51.00 price target on the stock. Two research analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $56.25.

Sensei Biotherapeutics Trading Up 5.7%

The company’s 50 day simple moving average is $31.58. The company has a market capitalization of $546.39 million, a price-to-earnings ratio of -0.15 and a beta of -0.29.

Sensei Biotherapeutics (NASDAQ:FTH) last posted its earnings results on Tuesday, August 4th. The company reported ($2.84) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($5.04) by $2.20. As a group, equities analysts predict that Sensei Biotherapeutics, Inc. will post -13.69 EPS for the current year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in FTH. Citadel Advisors LLC acquired a new stake in Sensei Biotherapeutics during the second quarter valued at $307,000. Alyeska Investment Group L.P. bought a new stake in shares of Sensei Biotherapeutics in the second quarter valued at approximately $3,610,000. Vivo Capital LLC bought a new position in shares of Sensei Biotherapeutics during the 1st quarter worth about $22,758,000. Bank of America Corp DE lifted its position in shares of Sensei Biotherapeutics by 10,692.5% in the 1st quarter. Bank of America Corp DE now owns 33,025 shares of the company’s stock worth $1,041,000 after acquiring an additional 32,719 shares during the period. Finally, Stempoint Capital LP acquired a new stake in Sensei Biotherapeutics during the first quarter worth $4,188,000. 10.50% of the stock is currently owned by institutional investors and hedge funds.

Sensei Biotherapeutics Company Profile

Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on developing cancer immunotherapies designed to activate the immune system against tumors. The company’s approach is intended to address immune suppression within the tumor microenvironment and potentially improve patients’ responses to existing cancer treatments.

Sensei’s pipeline has included antibody-based and vaccine-based immunotherapies. Its lead programs have included SNS-101, an antibody designed to target the VISTA immune checkpoint, and earlier ImmunoPhage-based programs intended to stimulate tumor-specific immune responses.